Laura Sarkisian1, Lotte Saaby1, Tina S Poulsen1, Oke Gerke2, Nikolaj Jangaard1, Susanne Hosbond1, Axel C P Diederichsen1, Kristian Thygesen3, Hans Mickley4. 1. Department of Cardiology, Odense University Hospital, Odense, Denmark. 2. Department of Nuclear Medicine, Odense University Hospital, and Centre of Health Economics Research, University of Southern Denmark, Odense, Denmark. 3. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. 4. Department of Cardiology, Odense University Hospital, Odense, Denmark. Electronic address: Hans.Mickley@rsyd.dk.
Abstract
BACKGROUND: Cardiac troponins have emerged as the preferred biomarkers for detecting myocardial necrosis and diagnosing myocardial infarction. However, current cardiac troponin assays do not discriminate between ischemic and nonischemic causes of myocardial cell death. Thus, when an increased troponin value is encountered in the absence of obvious myocardial ischemia, a careful search for other clinical conditions is crucial. METHODS: In 2010 to 2011, we prospectively studied hospitalized patients who had cardiac troponin I measured on clinical indication. An acute myocardial infarction was diagnosed in cases of a cardiac troponin I increase or decrease pattern with at least 1 value >30 ng/L (99th percentile) together with myocardial ischemia. Myocardial injury was defined as cardiac troponin I values >30 ng/L, but without signs or symptoms indicating overt cardiac ischemia. Patients with peak values ≤30 ng/L were classified as nonelevated cardiac troponin I. Follow-up was at least 3 years with all-cause mortality as the sole clinical end point. RESULTS: A total of 3762 patients were included. Of these, 488 (13%) had acute myocardial infarction, 1089 (29%) had myocardial injury, and 2185 (58%) had nonelevated cardiac troponin I values. Patients with myocardial injury frequently presented with dyspnea, were older, and had more comorbidity than patients in the 2 other groups. During a median follow-up of 3.2 years, 1342 patients died. Mortality differed significantly between groups: 39% in those with myocardial infarction, 59% in those with myocardial injury, and 23% in those with nonelevated cardiac troponin I (log-rank test; P < .0001). No significant difference in mortality between patients with type 2 myocardial infarction and patients with myocardial injury was observed (63% and 59%, respectively). CONCLUSIONS: Patients with myocardial injury are older and have more comorbidity than those with acute myocardial infarction. Both groups exhibit a poorer prognosis than patients with nonelevated cardiac troponin I values. Of note, a very high long-term mortality is observed in patients with type 2 myocardial infarction and patients with myocardial injury.
BACKGROUND: Cardiac troponins have emerged as the preferred biomarkers for detecting myocardial necrosis and diagnosing myocardial infarction. However, current cardiac troponin assays do not discriminate between ischemic and nonischemic causes of myocardial cell death. Thus, when an increased troponin value is encountered in the absence of obvious myocardial ischemia, a careful search for other clinical conditions is crucial. METHODS: In 2010 to 2011, we prospectively studied hospitalized patients who had cardiac troponin I measured on clinical indication. An acute myocardial infarction was diagnosed in cases of a cardiac troponin I increase or decrease pattern with at least 1 value >30 ng/L (99th percentile) together with myocardial ischemia. Myocardial injury was defined as cardiac troponin I values >30 ng/L, but without signs or symptoms indicating overt cardiac ischemia. Patients with peak values ≤30 ng/L were classified as nonelevated cardiac troponin I. Follow-up was at least 3 years with all-cause mortality as the sole clinical end point. RESULTS: A total of 3762 patients were included. Of these, 488 (13%) had acute myocardial infarction, 1089 (29%) had myocardial injury, and 2185 (58%) had nonelevated cardiac troponin I values. Patients with myocardial injury frequently presented with dyspnea, were older, and had more comorbidity than patients in the 2 other groups. During a median follow-up of 3.2 years, 1342 patients died. Mortality differed significantly between groups: 39% in those with myocardial infarction, 59% in those with myocardial injury, and 23% in those with nonelevated cardiac troponin I (log-rank test; P < .0001). No significant difference in mortality between patients with type 2 myocardial infarction and patients with myocardial injury was observed (63% and 59%, respectively). CONCLUSIONS:Patients with myocardial injury are older and have more comorbidity than those with acute myocardial infarction. Both groups exhibit a poorer prognosis than patients with nonelevated cardiac troponin I values. Of note, a very high long-term mortality is observed in patients with type 2 myocardial infarction and patients with myocardial injury.
Authors: Simon A Mahler; Jason P Stopyra; Fred S Apple; Robert F Riley; Gregory B Russell; Brian C Hiestand; James W Hoekstra; Cedric W Lefebvre; Bret A Nicks; David M Cline; Kim L Askew; David M Herrington; Gregory L Burke; Chadwick D Miller Journal: Clin Biochem Date: 2017-01-10 Impact factor: 3.281
Authors: Cian P McCarthy; Muthiah Vaduganathan; Avinainder Singh; Zirui Song; Ron Blankstein; Hanna K Gaggin; Jason H Wasfy; James L Januzzi Journal: J Am Coll Cardiol Date: 2018-09-04 Impact factor: 24.094
Authors: Andrew R Chapman; Philip D Adamson; Anoop S V Shah; Atul Anand; Fiona E Strachan; Amy V Ferry; Kuan Ken Lee; Colin Berry; Iain Findlay; Anne Cruikshank; Alan Reid; Alasdair Gray; Paul O Collinson; Fred Apple; David A McAllister; Donogh Maguire; Keith A A Fox; Catalina A Vallejos; Catriona Keerie; Christopher J Weir; David E Newby; Nicholas L Mills Journal: Circulation Date: 2019-10-07 Impact factor: 29.690
Authors: John Hung; Andreas Roos; Erik Kadesjö; David A McAllister; Dorien M Kimenai; Anoop S V Shah; Atul Anand; Fiona E Strachan; Keith A A Fox; Nicholas L Mills; Andrew R Chapman; Martin J Holzmann Journal: Eur Heart J Date: 2021-07-08 Impact factor: 35.855